Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
This study investigated the allegedly causal relationship between microglial activation and neurofibrillary degeneration (NFD) typical of Alzheimer's disease (AD) by determining if presence of extreme microglial activation coincides with intensified NFD. We performed comparative histopathological analyses of NFD and microglial reactivity in 18 primary subjects ranging from 4 to 51 years of age. Ten of these subjects (median age 34) died from infectious disease (HIV, sepsis) and CNS trauma, while eight subjects (median age 32.5) died from non‐infectious conditions (controls). Second, we also examined two 52‐year‐old subjects with Down syndrome where one had comorbid sepsis and the other one did not. We found that all 10 subjects with infectious/traumatic diagnoses showed severe neuroinflammation, while the 8 control subjects completely lacked neuroinflammatory changes. However, all 18 primary subjects were found to show the same early‐stage, pretangle neuropathology of Braak stage 1a and 1b, that is, they exhibited primarily subcortical NFD in the locus coeruleus and sporadic lesions in the transentorhinal cortex. Similarly, the two subjects with Down syndrome showed the same high levels of NFD (Braak stage VI) irrespective of the comorbid sepsis‐related neuroinflammation present in one of these individuals. Collectively, our findings show that despite rampant microglial activation in all subjects with neuroinflammatory conditions the extent of NFD is at the same level as seen in non‐inflamed controls. These findings demonstrate that microglial activation does not initiate or exacerbate NFD, and we conclude that CNS inflammation is unlikely to be causally involved in the development of NFD characteristic of AD dementia. GLIA 2013;62:96–105
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 5×
“…of neuroinflammation (sepsis, HIV infection, toxoplasmosis, head injury; cases 1–10 in Table 1) were selected from a larger cohort of subjects that had been previously characterized in terms of presence and extent of AD-type neuropathology (Braak and Del Tredici, 2011a,b; Braak et al., 2011).”
BackgroundMethodInfluentialSelf-citationInflammation and white matter degeneration persist for years after a single traumatic brain injury
Johnson, V. E., Stewart, J. E., Begbie, F. D., Trojanowski, J. Q., Smith, D. H., & Stewart, W. (2013) · Brain · doi:10.1093/brain/aws322 · Cited by 1,045
Microglia as neuroprotective, immunocompetent cells of the CNS
Streit, W. J. (2002) · Glia · doi:10.1002/glia.10154 · Cited by 919
Self-citationMcGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · cited 4×
“…the features that have been used to support a role for harmful inflammation in AD neurodegeneration are, (a) presence of HLA-DR-positive microglia (McGeer et al., 1987), (b) presence of microglial clusters around Ab deposits (Sasaki et al., 1997), and (c) presence of interleukin-1 (IL-1)…”
BackgroundInfluentialThe pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Self-citationStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727 · cited 6×
“Moreover, prior and current observations from our laboratory (Streit et al., 2009), as well as from others (Lemstra et al., 2007; Mattiace et al., 1990), have shown that microglial activation occurs in the CNS of subjects with sepsis.”
BackgroundMethodInfluentialSelf-citationDystrophic microglia in the aging human brain
Streit, W. J., Sammons, N. W., Kuhns, A. J., & Sparks, D. L. (2004) · Glia · doi:10.1002/glia.10319 · Cited by 705 · cited 1×
“…not only absence of activated microglia in both aged as well as AD and DS brain, but instead a prevalence of degenerating (dystrophic) microglia particularly in cortical areas prone to first developing tau pathology, such as the entorhinal cortex (Streit et al., 2009, 2004; Xue and Streit, 2011).”
BackgroundSelf-citationIRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Graeber, M. B. (2010) · Science · doi:10.1126/science.1190929 · Cited by 608
Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections
Braak, H., & Braak, E. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00661.x · Cited by 598 · cited 3×
“…our study are important because neurofibrillary degeneration provides the best correlate to clinical symptoms of dementia (Arriagada et al., 1992; Braak and Braak, 1991b; Streit et al.: Neuroinflammation and Tau Pathology January 2014 99 Grober et al., 1999; Riley et al., 2002; Thal et al.,…”
BackgroundMethodSelf-citationCroisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Microglial senescence: does the brain's immune system have an expiration date?
Streit, W. J. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.001 · Cited by 397 · cited 1×
“…to the neuroinflammation theory, we propose that NFD occurs because of deteriorating microglial cell functions and progressive microglial degeneration (microglial dystrophy), a topic discussed previously as the microglial dysfunction hypothesis (Conde and Streit, 2006; Streit, 2002, 2004, 2006).”
BackgroundSelf-citationMicroglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Conde, J. R., & Streit, W. J. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000202887.22082.63 · Cited by 344
Self-citationMicroglia and Alzheimer's disease pathogenesis
Streit, W. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20093 · Cited by 335 · cited 1×
“…to the neuroinflammation theory, we propose that NFD occurs because of deteriorating microglial cell functions and progressive microglial degeneration (microglial dystrophy), a topic discussed previously as the microglial dysfunction hypothesis (Conde and Streit, 2006; Streit, 2002, 2004, 2006).”
BackgroundSelf-citationCause of death in patients with dementia disorders
Brunnström, H. R., & Englund, E. M. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02503.x · Cited by 246
Alzheimer disease and Down syndrome: factors in pathogenesis
Lott, I. T., & Head, E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.005 · Cited by 212
Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187
Variant TREM2 as Risk Factor for Alzheimer's Disease
Neumann, H., & Daly, M. J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1213157 · Cited by 177
Microglial activation in early stages of amyloid β protein deposition
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997) · Acta Neuropathologica · doi:10.1007/s004010050713 · Cited by 132 · cited 2×
“…for harmful inflammation in AD neurodegeneration are, (a) presence of HLA-DR-positive microglia (McGeer et al., 1987), (b) presence of microglial clusters around Ab deposits (Sasaki et al., 1997), and (c) presence of interleukin-1 (IL-1) immunoreactivity (Griffin et al., 1989; Sheng et al., 1997).”
BackgroundPrevalence, incidence and duration of Braak's stages in the general population: can we know?
Duyckaerts, C., & Hauw, J.-J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00047-x · Cited by 109
Macrosialin increases during normal brain aging are attenuated by caloric restriction
Wong, A. M., Patel, N. V., Patel, N. K., Wei, M., Morgan, T. E., de Beer, M. C., de Villiers, W. J. S., & Finch, C. E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.07.058 · Cited by 85 · cited 2×
“…it is difficult to reconcile such prolonged lingering of macrophages in the corpus callosum with the onset of NFD in the temporal lobe, or with the effects of aging which include naturally increased expression of these antigens on senescent microglial cells (Perry et al., 1993; Wong et al., 2005).”
BackgroundEffect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Halliday, G. M., Shepherd, C. E., McCann, H., Reid, W. G. J., Grayson, D. A., Broe, G. A., & Kril, J. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.831 · Cited by 72
Thal, D. R., Arendt, T., Waldmann, G., Holzer, M., Zedlick, D., Rüb, U., & Schober, R. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00090-6 · Cited by 53 · cited 1×
“…et al., 1992; Braak and Braak, 1991b; Streit et al.: Neuroinflammation and Tau Pathology January 2014 99 Grober et al., 1999; Riley et al., 2002; Thal et al., 1998), and it therefore seems obvious that continued pursuit of antiinflammatory strategies for treatment or prevention of AD dementia…”
Background
Cited by
Streit, W. J., Xue, Q.-S., Tischer, J., & Bechmann, I. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0142-6 · Cited by 317
“Additional concerns are raised by findings showing that, a) tau pathology occurs in the absence of Aβ deposits and in the absence of microglial activation [89-91]; b) administration of anti-inflammatory drugs does not slow or reverse tau pathology or cognitive decline [92-94]; c) tau pathology is not initiated or exac…”
BackgroundSelf-citationOxidized cholesterol as the driving force behind the development of Alzheimer’s disease
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00119 · Cited by 180
Microglial activation occurs late during preclinical Alzheimer's disease
Streit, W. J., Braak, H., Del Tredici, K., Leyh, J., Lier, J., Khoshbouei, H., Eisenlöffel, C., Müller, W., & Bechmann, I. (2018) · Glia · doi:10.1002/glia.23510 · Cited by 98
Self-citationHuman CNS immune senescence and neurodegeneration
Streit, W. J., & Xue, Q.-S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.05.005 · Cited by 86
Self-citation
Metadata
- Authors
- Streit, W. J., Xue, Q., Braak, H., & del Tredici, K.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2013-11-04
- Volume
- 62
- Issue
- 1
- Pages
- 96-105
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2118450265
- Cited by
- 24
- References
- 26
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.